Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40256-020-00429-7 http://scihub22266oqcxt.onion/10.1007/s40256-020-00429-7 32737841!7394926!32737841     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32737841&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Am+J+Cardiovasc+Drugs 2020 ; 20 (5): 413-418 Nephropedia Template TP {{tp|p=32737841|t=2020. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?|pdf=|usr=}}{{32737841}} gab.com Text Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection JO: Am J Cardiovasc Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32737841 #FOAvip Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence. Twit Text FOAVip Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection ????Am J Cardiovasc Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32737841 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32737841 #FOAvip English Wikipedia <ref>{{Cite pmid|32737841}}</ref> Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection? #MMPMID32737841 Sanchis-Gomar F; Lavie CJ; Morin DP; Perez-Quilis C; Laukkanen JA; Perez MV Am J Cardiovasc Drugs 2020[Oct]; 20 (5): 413-418 PMID32737841show ga Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence. |*Arrhythmias, Cardiac/drug therapy/virology[MESH] |*Betacoronavirus/drug effects/physiology[MESH] |*Coronavirus Infections/drug therapy/metabolism/physiopathology/prevention & control[MESH] |*Pandemics/prevention & control[MESH] |*Pneumonia, Viral/drug therapy/metabolism/physiopathology/prevention & control[MESH] |Amiodarone/*pharmacology[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Anti-Arrhythmia Agents/pharmacology[MESH] |Antiviral Agents/pharmacology[MESH] |COVID-19[MESH] |Humans[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH] |Treatment Outcome[MESH]Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Onl(epmc).pdf DeepDyve Pubget Overpricing